Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.80 |
| ▸ | ADRB3 | P13945 | 12/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8976032 | 1.00 | ALOX15 (0.80) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL8976435 | 0.99 | ALOX15 (0.82) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL8976317 | 0.99 | ALOX15 (0.82) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| Talibegron SCHEMBL3699503 | 0.90 | ALOX15 (0.97) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| Talibegron SCHEMBL6060362 | 0.90 | ALOX15 (0.97) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| Talibegron SCHEMBL328977 | 0.90 | ALOX15 (0.97) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| SCHEMBL11525140 | 0.89 | ALOX15 (0.64) | ALOX15ADRB3ADRB1KDM4ETDP1 | |
| Talibegron SCHEMBL1230810 | 0.89 | ALOX15 (1.00) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| Talibegron SCHEMBL8976330 | 0.89 | ALOX15 (1.00) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E | |
| SCHEMBL8976399 | 0.87 | ALOX15 (0.78) | ALOX15ADRB3ADRB1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0516349-B1 | 2-Hydroxy-2-phenylethylamine derivatives as beta-3-adrenoceptor agonists | ZENECA LTD (GB) | 1995-09-20 | — | — | EP | claimed |
| US-5393779-A | Anti-obesity, hypoglycemic, adrenergic blocking agents | ZENECA LIMITED (GB) | 1995-02-28 | — | — | US | claimed |
| EP-0516349-A2 | 2-Hydroxy-2-phenylethylamine derivatives as beta-3-adrenoceptor agonists | ZENECA LIMITED (GB) | 1992-12-02 | — | — | EP | claimed |
| US-5480910-A | 4-(2-(2-HYDROXY-2-PHENYLETHYLAMINO)ETHOXY)PHENYLACETIC ACID OR SALT IS ADMINISTERED FOR GASTROINTESTINAL DISORDERS | ZENECA LIMITED (GB) | 1996-01-02 | — | — | US | disclosed |
| EP-0516349-B1 | 2-Hydroxy-2-phenylethylamine derivatives as beta-3-adrenoceptor agonists | ZENECA LTD (GB) | 1995-09-20 | — | — | EP | disclosed |
| US-5434184-A | B3-adrenoceptor agonist | ZENECA LIMITED (GB) | 1995-07-18 | — | — | US | disclosed |
| US-5393779-A | Anti-obesity, hypoglycemic, adrenergic blocking agents | ZENECA LIMITED (GB) | 1995-02-28 | — | — | US | disclosed |
| EP-0516349-A2 | 2-Hydroxy-2-phenylethylamine derivatives as beta-3-adrenoceptor agonists | ZENECA LIMITED (GB) | 1992-12-02 | — | — | EP | disclosed |